spacer
home > epc > Summer 2010
PUBLICATIONS

European Pharmaceutical Contractor

epc
Summer 2010

European Pharmaceutical Contractor (EPC) is designed to fill a unique position in pharmaceutical publishing. Providing a dedicated platform of communication and information for the international pharmaceutical contract market, it consists of a series of articles and case studies written by eminent figures in contractor groups and traditional multinational pharmaceutical companies.

   
Text
PDF
bullet
Marketplace & Business
Despite the difficult economic times, the market for toxicology and animal pharmacology CROs remains strong. Graham Hughes, EPC's Editor points out some emerging trends as the pharma industry moves forward.  
view
download pdf
During the past 10 years, the number of biopharmaceuticals in the market has exploded and we expect this trend to continue. Scott E Boley of MPI Research highlights the differences between biopharmaceuticals and their predecessor small molecules, with respect to nonclinical development.  
view
download pdf
When it comes to making decisions, are you overwhelmed by too many options? Choosing the right outsourcing partner is crucial and the selection process can be made simpler if you consider the key factors identified by David Tudbury and Vikki Renwick at Tepnel Pharma Services.  
view
download pdf
Marina Gornostai of Dila and Oleksii Mikheiev of Verum highlight the regulatory changes concerning clinical trials in Ukraine and the advantages of conducting trials in the region.  
view
download pdf
Sabine Hutchison, Susan Philippo and Ron van Eijsden of Docs Global discuss the effect of the wave of redundancies in the pharma and biotech industries, and consider how this challenging economic environment will cause organisations to approach staffing in a new and flexible way.  
view
download pdf
bullet
Legal & Regulatory
Globalisation of the pharmaceutical market means new drugs can have extensive patient exposure over a short period of time and thus proactive pharmacovigilance is imperative. Alison Bond and Katherine Hutchinson at Quanticate emphasise how integrating safety checks throughout the drug development process will help to achieve this aim.  
view
download pdf
Outsourcing regulatory affairs offers significant benefits, but it can also present real issues if not approached in the right way. Jonathan Trethowan of TRAC outlines some key questions to ask in order to ensure you reap only the benefits.  
view
download pdf
As Suzanne Rab and Robert F Leibenluft of Hogan Lovells look at some cases of the UK Office of Fair Trading versus pharma companies regarding competition and generic substitutes, one wonders if we really can determine when an ‘incremental improvement’ is important enough to avoid antitrust violation.  
view
download pdf
bullet
Clinical Development
A clinical trial cannot exist without the patients, thus their recruitment and retention are two critical targets to reduce trial timelines. Graham Wylie of the Medical Research Network provides a model with some effective tools and techniques.  
view
download pdf
The phrase 'time is money' certanily applies to pharmaceuticals; Graham Woods of Cetero Research illustrates how to safely accelerate through the drug development race track and shorten the journey from proof-of-concept to first-in-human studies.  
view
download pdf
When it comes to the safety of new medicines and vaccines, monitoring for adverse side effects should be carried out more actively post-market. Marco Hoekendijk and Arnold Chan at i3 Drug Safety highlight the importance of this approach citing the H1N1 vaccine as an example.  
view
download pdf
bullet
Data Management & IT Solutions
Do you know your EDC from your IVR/IWR, DDC, RFD and EHR, and have a grasp of their differences and benefits? Ross Rothmeier at Covance discusses electronic data and the need to adapt and integrate it with other systems, such as an electronic trial management system, to improve the efficiency of drug development.  
view
download pdf
EDC might be the norm for clinical studies today but software on its own will not increase efficiency; Debra Jendrasek and Greg Johnson at Chiltern describe the importance of good leadership for a successful study.  
view
download pdf
bullet
LABS & Logistics
Lori A Ball of Biostorage Technologies stresses the importance of logistics in the clinical research process and how the right logistical service partner and efficient cold chain management can result in cost and time savings.  
view
download pdf
The recent disruptions due to the Eyjafjallajökull volcano have highlighted how dependent we are on efficient transport systems. Eric Newman at ProTecht Risk Solutions identifies climatic conditions as one of the factors to consider when developing an effective cold chain management programme.  
view
download pdf
bullet
SPECIAL FEATURE: ONCOLOGY
Edwin Klumper of SMS-oncology delves into the ‘whats’ and ‘whys’ of personalised medicine for the treatment of cancers, and the advantages it could hold for patients and drug companies alike.  
view
download pdf
Standardised oncology assessment criteria are essential to the validity of oncology clinical trial outcome data, explain Stephen Bates and Kelie Luby at Perceptive Informatics.  
view
download pdf
   
spacer



Published quarterly in
February, May,
August and November

News and Press Releases

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

Industry Events

Clinical Trial Supply Southeast 2018

2-3 October 2018, Cary, North Carolina

Clinical Trial Supply Southeast will return to Cary, North Carolina for fall 2018. Part of our global series of events, this show will attract the leading biotech and pharma companies from the Southeast region, the event will focus on how companies can adapt their supply chains to fit into the highly regulated world.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement